Timeline
Scrub through the years. Approvals, landmark trials, cancer history events, and roadmap eras appear as they stood in the chosen year, all derived from dated records in the corpus.
2026
1940195019601970198019902000201020202030
72
products approved to date
41
landmark trials reported to date
14
roadmap eras active
This year: 2026
Approvals (9)
- Durvalumab · US · High-risk NMIBC with BCG
- Florastamin F-18 · South Korea · PET imaging of PSMA-positive lesions in men with prostate cancer whose existing imaging suggests recurrence or metastasis
- Floretyrosine F-18 (FET) · US · Use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients 1 month of age and older
- Florquinitau F-18 · US · PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease, to identify patients with tau neurofibrillary tangle pathology
- Lutetium-177 dotatate (radioligand equivalent) · US · Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut and hindgut tumours, in adults
- Lutetium-177 vipivotide tetraxetan · US · Label expansion (July 2026)
- Pembrolizumab · US · Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
- Piflufolastat F-18 / Pylarify TruVu · US · Pylarify TruVu formulation
- Technetium (99mTc) pexiretide · China · SPECT/CT assessment of regional lymph-node metastasis in patients with suspected lung cancer
Trials reported (1)
- PRINCE Completed ·
History events (18)
- Diffuse large B-cell lymphoma: frontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA
- Follicular lymphoma: Tazemetostat withdrawn worldwide · Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.
- Glioma & glioblastoma: ASCO 2026: NeoVax personalised vaccine immune responses; multi-target CAR-T; tovorafenib EU approval
- Hepatocellular carcinoma: EMERALD-3 positive for PFS; LEAP-012 final OS HR 0.98; IMbrave050 update negative; third camrelizumab-rivoceranib CRL (23 July)
- HER2-positive breast cancer: T-DXd approved in early-stage disease
- HER2-positive breast cancer: T-DXd approved neoadjuvant and post-neoadjuvant; palbociclib maintenance for HR+/HER2+ (PATINA)
- Intermediate hepatocellular carcinoma: EMERALD-3: durvalumab-tremelimumab plus TACE reported positive
- Metastatic hormone-sensitive prostate cancer: Capivasertib for PTEN-deficient and 177Lu-PSMA-617 for PSMA-positive disease approvedPSMAdditionLutetium-177 vipivotide tetraxetan
- Neuroblastoma: ANBL1531 MIBG randomisation maturing; ALK arm reportsCOG ANBL1531
- Neuroendocrine tumours: FDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS177Lu-edotreotideACTION-1
- Non-small cell lung cancer: China approves technetium (99mTc) pexiretide for nodal staging · NMPA approval on 2 April 2026 of an integrin alpha-v-beta-3 RGD peptide for SPECT/CT assessment of regional lymph nodes in suspected lung cancer.Technetium (99mTc) pexiretide
- Prostate cancer: Pluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient diseasePSMAdditionLutetium-177 vipivotide tetraxetan
- Renal cell carcinoma: LITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls short
- Small-cell lung cancer: Phase 3 readouts pending for I-DXd and tarlatamab maintenance
- Thyroid cancer: Selpercatinib label update (July 2026)
- Triple-negative breast cancer: FDA approves datopotamab deruxtecan for first-line metastatic TNBC in patients ineligible for PD-1/PD-L1 therapy · Based on TROPION-Breast02, with median overall survival of 23.7 versus 18.7 months, approved 22 May 2026.
- Triple-negative breast cancer: FDA approves sacituzumab govitecan, alone or with pembrolizumab, for first-line metastatic TNBC · Based on ASCENT-03 and ASCENT-04/KEYNOTE-D19, approved 24 June 2026.
- Urothelial cancer: Perioperative pembrolizumab plus enfortumab vedotin indication expanded to cisplatin-eligible muscle-invasive bladder cancer · Based on KEYNOTE-B15/EV-304 in 808 patients, a 47% reduction in event-free survival events versus neoadjuvant chemotherapy and surgery.
Roadmap eras active (14)
- Alpha-emitter roadmap · 2024-2026: Supply scales and the first phase 2 readouts land current
- Alpha-emitter roadmap · 2026-2029: Phase 3 readouts and a step-change in actinium-225 capacity emerging
- Dosimetry roadmap · 2024-2028: Emerging: faster quantitative imaging for routine dosimetry emerging
- Isotope supply roadmap · 2024-2026: Accelerator-made actinium-225 reaches commercial scale current
- Isotope supply roadmap · 2026-2029: Building twentyfold actinium-225 capacity emerging
- Molecular imaging roadmap · 2018-2026: Stromal PET and total-body scanners current
- Molecular imaging roadmap · 2024-2028: Drug-target and immune PET emerging
- Neuro-oncology imaging roadmap · 2020-2026: 68Ga-DOTATATE PET in routine meningioma management current
- Neuro-oncology imaging roadmap · 2025-2028: Emerging: SSTR2 theranostics extends into meningioma therapy emerging
- PSMA theranostics roadmap · 2024-2028: Alpha-emitting PSMA ligands after 177Lu-PSMA emerging
- Radiopharmaceutical roadmap · 2023-2026: Earlier lines, consolidation, and an M&A wave current
- Radiopharmaceutical roadmap · 2026-2029: Alpha emitters and new targets emerging
- SSTR theranostics roadmap · 2022-2026: Alpha-emitting SSTR radioligands after beta PRRT current
- SSTR theranostics roadmap · 2025-2028: Emerging: SSTR2 theranostics in meningioma emerging
Standard of care in 2026 derived
Best effort: for each cancer, the most recent dated history event at or before 2026 that references products or technologies. Not a guideline; see each cancer page for the current standard of care.
- Biochemical recurrence of prostate cancer (2023) · EMBARK: enzalutamide delays metastasis in high-risk biochemical recurrence
- Diffuse large B-cell lymphoma (2014) · Lugano classification unifies PET-based staging and response
- Follicular lymphoma (2011) · PRIMA: rituximab maintenance
- Glioma & glioblastoma (1999) · Temozolomide approved (anaplastic astrocytoma)
- Grade 3 well-differentiated neuroendocrine tumour (2024) · NETTER-2: first-line lutetium-177 dotatate in grade 2 to 3 tumours with Ki-67 up to 55 percent
- Hepatocellular carcinoma (2017) · RESORCE: regorafenib, first second-line benefit; SARAH/SIRveNIB negative for Y-90 vs sorafenib
- HER2-positive breast cancer (2024) · PHERGain chemotherapy omission; DESTINY-Breast12 brain metastases; zanidatamab approved (BTC)
- Hereditary pheochromocytoma and paraganglioma (2000) · SDHD mutations found in familial head and neck paraganglioma; SDHB follows in 2001
- High-risk neuroblastoma (1985) · Iodine-131 MIBG therapy first given for neuroblastoma
- Localised prostate cancer, high and very high risk (2022) · STAMPEDE: abiraterone improves survival in high-risk non-metastatic disease
- Lung neuroendocrine tumours (2025) · Cabozantinib approved for previously treated neuroendocrine tumours including lung; ESMO subgroup analysis
- Metastatic castration-resistant prostate cancer (2025) · ECLIPSE: 177Lu-PSMA-I&T meets its endpoint
- Metastatic hormone-sensitive prostate cancer (2026) · Capivasertib for PTEN-deficient and 177Lu-PSMA-617 for PSMA-positive disease approved
- Metastatic pheochromocytoma and paraganglioma (2024) · FIRSTMAPPP: sunitinib improves progression-free survival; Azedra withdrawn from the market
- Multiple endocrine neoplasia syndromes (2015) · ATA guideline: codon-based timing of prophylactic thyroidectomy
- Neuroblastoma (2026) · ANBL1531 MIBG randomisation maturing; ALK arm reports
- Neuroendocrine and small-cell prostate cancer (2024) · Tarlatamab shows activity against DLL3-positive neuroendocrine prostate cancer
- Neuroendocrine tumours (2026) · FDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS
- Non-metastatic castration-resistant prostate cancer (2020) · All three trials report longer overall survival
- Non-small cell lung cancer (2026) · China approves technetium (99mTc) pexiretide for nodal staging
- Osteosarcoma (2019) · Regorafenib (SARC024, REGOBONE) and cabozantinib (CABONE) show activity at relapse
- Pancreatic neuroendocrine tumours (2025) · Cabozantinib approved; COMPETE published
- Pheochromocytoma and paraganglioma (2024) · FIRSTMAPPP: sunitinib delays progression
- Prostate cancer (2026) · Pluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient disease
- Renal cell carcinoma (2023) · COSMIC-313 triplet fails on OS; CONTACT-03 closes IO rechallenge; belzutifan approved after IO/TKI (LITESPARK-005); ZIRCON validates CAIX PET
- Small intestinal neuroendocrine tumours (2025) · Cabozantinib approved for previously treated neuroendocrine tumours; COMPETE published
- Small-cell lung cancer (2019) · CASPIAN confirms chemo-immunotherapy with durvalumab
- Thyroid cancer (2025) · IoN confirms omission of radioiodine in low-risk disease (Lancet)
All products approved by 2026 (72)
Radioactive iodine (I-131) 1951Sodium fluoride F-18 1972Technetium Tc-99m medronate (MDP) 1972Gallium citrate Ga-67 1976Technetium Tc-99m pyrophosphate 1976Thallous chloride Tl-201 1977Technetium Tc-99m albumin aggregated (MAA) 1987Rubidium Rb-82 chloride 1989Technetium Tc-99m sestamibi 1990Strontium-89 chloride 1993Fludeoxyglucose F-18 (FDG) 1994Indium-111 pentetreotide 1994Technetium-99m exametazime (brain perfusion) 1994Dexrazoxane 1995Docetaxel 1996Technetium Tc-99m tetrofosmin 1996Rituximab 1997Samarium-153 lexidronam 1997Capecitabine 1998Thyrotropin alfa 1998Temozolomide 1999Ioflupane I-123 2000Ibritumomab tiuxetan 2002Yttrium-90 resin microspheres 2002Iodine-131 tositumomab 2003Fludeoxyglucose F-18 (brain metabolism) 2004Sorafenib 2005Sunitinib 2006Ammonia N-13 2007Iobenguane I-123 2008Iobenguane I-123 (cardiac use) 2008Everolimus 2009Cabazitaxel 2010Abiraterone acetate 2011Cabozantinib 2012Choline C-11 2012Enzalutamide 2012Florbetapir F-18 2012Pasireotide 2012Flutemetamol F-18 2013Radium-223 dichloride 2013Technetium-99m tilmanocept 2013Florbetaben F-18 2014Olaparib 2014Pembrolizumab 2014Holmium-166 microspheres 2015Rhenium-188 skin cancer therapy 2015Fluciclovine F-18 2016Gallium-68 DOTATATE (and Cu-64 DOTATATE) 2016Gallium-68 edotreotide (DOTATOC) 2016Durvalumab 2017Lutetium-177 dotatate 2017Iobenguane I-131 (therapeutic) 2018Fluorodopa F-18 2019Copper-64 dotatate 2020Flortaucipir F-18 2020Fluoroestradiol F-18 (FES PET) 2020Gallium-68 gozetotide (PSMA-11) 2020Donafenib 2021Illuccix (kit for Ga-68 gozetotide) 2021Piflufolastat F-18 / Pylarify TruVu 2021Yttrium-90 glass microspheres 2021Locametz (kit for Ga-68 gozetotide) 2022Lutetium-177 vipivotide tetraxetan 2022Flotufolastat F-18 2023Technegas (technetium Tc-99m labelled carbon inhalation aerosol) 2023Flurpiridaz F-18 2024Florastamin F-18 2026Floretyrosine F-18 (FET) 2026Florquinitau F-18 2026Lutetium-177 dotatate (radioligand equivalent) 2026Technetium (99mTc) pexiretide 2026